ERBB2 and breast cancer: In a prior study, it was reported that dasatinib inhibited EGFR, HER-2 and HER-3 expression in breast cancer cells, specifically the cell lines MDA-MB-468, SKBR3, MDA-MB-453, and MDA-MB-231[29].